DE60220018T2 - Hybridisierungspuffer die niedermolekulares dextransulfat verwenden und methoden zu deren verwendung - Google Patents
Hybridisierungspuffer die niedermolekulares dextransulfat verwenden und methoden zu deren verwendung Download PDFInfo
- Publication number
- DE60220018T2 DE60220018T2 DE60220018T DE60220018T DE60220018T2 DE 60220018 T2 DE60220018 T2 DE 60220018T2 DE 60220018 T DE60220018 T DE 60220018T DE 60220018 T DE60220018 T DE 60220018T DE 60220018 T2 DE60220018 T2 DE 60220018T2
- Authority
- DE
- Germany
- Prior art keywords
- dextran sulfate
- hybridization
- molecular weight
- probe
- tissue section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000009396 hybridization Methods 0.000 title claims abstract description 108
- 239000000872 buffer Substances 0.000 title claims abstract description 96
- 229960000633 dextran sulfate Drugs 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000000523 sample Substances 0.000 claims description 77
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 47
- 238000007901 in situ hybridization Methods 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 12
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 12
- 238000010186 staining Methods 0.000 claims description 12
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000003298 DNA probe Substances 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 4
- 229940038773 trisodium citrate Drugs 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 108020004518 RNA Probes Proteins 0.000 claims description 3
- 239000003391 RNA probe Substances 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002224 dissection Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 33
- 238000006243 chemical reaction Methods 0.000 abstract description 27
- 230000007717 exclusion Effects 0.000 abstract description 23
- 239000003795 chemical substances by application Substances 0.000 abstract description 20
- 238000002156 mixing Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 57
- 210000001519 tissue Anatomy 0.000 description 42
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 241000701806 Human papillomavirus Species 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108700020302 erbB-2 Genes Proteins 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000000018 DNA microarray Methods 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 108020003215 DNA Probes Proteins 0.000 description 5
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000019263 trisodium citrate Nutrition 0.000 description 4
- 108020003217 Nuclear RNA Proteins 0.000 description 3
- 102000043141 Nuclear RNA Human genes 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 101710180319 Protease 1 Proteins 0.000 description 3
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- AVJBPWGFOQAPRH-MMPMEFKSSA-N beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 AVJBPWGFOQAPRH-MMPMEFKSSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 108700029227 Immunoglobulin Light Chain Genes Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 101100481002 Mus musculus Tff1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010068322 Oral papilloma Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- -1 dextran sulfates Chemical class 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US772123 | 2001-01-29 | ||
| US09/772,123 US6656685B2 (en) | 2001-01-29 | 2001-01-29 | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| PCT/US2002/002642 WO2002061139A2 (en) | 2001-01-29 | 2002-01-29 | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60220018D1 DE60220018D1 (de) | 2007-06-21 |
| DE60220018T2 true DE60220018T2 (de) | 2008-01-10 |
Family
ID=25093987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60220018T Expired - Fee Related DE60220018T2 (de) | 2001-01-29 | 2002-01-29 | Hybridisierungspuffer die niedermolekulares dextransulfat verwenden und methoden zu deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6656685B2 (enExample) |
| EP (1) | EP1356116B1 (enExample) |
| JP (1) | JP2005503762A (enExample) |
| AT (1) | ATE361995T1 (enExample) |
| AU (1) | AU2002240180B2 (enExample) |
| CA (1) | CA2434854A1 (enExample) |
| DE (1) | DE60220018T2 (enExample) |
| WO (1) | WO2002061139A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1385999B1 (en) * | 2001-04-30 | 2012-12-12 | Ventana Medical Systems, Inc. | Reagents and methods for automated in situ or microarray hybridization |
| WO2005033333A2 (en) * | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
| DE102004028303A1 (de) * | 2004-06-11 | 2005-12-29 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zum Nachweis von Analyten |
| EP2057289B1 (en) * | 2006-08-09 | 2016-08-10 | Univ Singapore | PROCESS FOR MOLECULAR BIOLOGICAL APPLICATIONS |
| CA3069091C (en) | 2006-11-01 | 2021-09-14 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| EP2636756B2 (en) | 2008-05-27 | 2019-11-20 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| US8703490B2 (en) | 2008-06-05 | 2014-04-22 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
| EP2401396B1 (en) | 2009-02-26 | 2016-11-23 | Dako Denmark A/S | Methods for performing a stringent wash step in hybridization applications |
| WO2011057017A1 (en) * | 2009-11-06 | 2011-05-12 | Bend Research, Inc. | Aqueous nanoparticle suspensions for use in drug discovery |
| EP2683814A4 (en) | 2011-03-11 | 2014-09-24 | Univ Singapore | PERIPHERAL BLOOD PERFECT PERFORMER |
| WO2013046033A1 (en) * | 2011-09-30 | 2013-04-04 | Dako Denmark A/S | Hybridization compositions and methods using formamide |
| EP3252173A1 (en) | 2011-10-21 | 2017-12-06 | Dako Denmark A/S | Hybridization compositions and methods |
| US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
| DK3133166T4 (da) * | 2015-08-21 | 2023-03-20 | 42 Life Sciences Gmbh & Co Kg | Sammensætning og fremgangsmåde til hybridisering |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| ES3008982T3 (en) | 2017-08-18 | 2025-03-25 | Neutrolis Inc | Engineered dnase enzymes and use in therapy |
| JP7431802B2 (ja) * | 2018-08-15 | 2024-02-15 | イルミナ インコーポレイテッド | ライブラリー富化を改善するための組成物および方法 |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| EP3864147A4 (en) | 2018-10-08 | 2022-07-06 | Neutrolis, Inc. | DNASE ENZYME ENGINEERING FOR MANUFACTURING AND THERAPY |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4302204A (en) * | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
| US4689294A (en) | 1984-11-19 | 1987-08-25 | Miles Laboratories, Inc. | Enhancement of hybridization of nucleic acids by anionic polymers |
| US5985549A (en) | 1985-10-22 | 1999-11-16 | University Of Massachusetts | Non-isotopic in-situ hybridization method for detection of nucleic acids |
| US5447841A (en) * | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US4886741A (en) * | 1987-12-09 | 1989-12-12 | Microprobe Corporation | Use of volume exclusion agents for the enhancement of in situ hybridization |
| US5273905A (en) * | 1991-02-22 | 1993-12-28 | Amoco Corporation | Processing of slide mounted material |
| US5750340A (en) | 1995-04-07 | 1998-05-12 | University Of New Mexico | In situ hybridization solution and process |
| US6127188A (en) * | 1995-10-06 | 2000-10-03 | Mj Research, Inc. | Method and apparatus for controlling evaporation in histological procedures |
| US5763185A (en) * | 1996-12-30 | 1998-06-09 | Becton Dickinson And Company | Method for reducing inhibitors of nucleic acid hybridization |
| CA2320750C (en) * | 1998-02-27 | 2004-08-24 | Ventana Medical Systems, Inc. | System and method of aspirating and dispensing reagent |
| US6855552B2 (en) * | 1998-09-03 | 2005-02-15 | Ventana Medical Systems | Automated immunohistochemical and in situ hybridization assay formulations |
-
2001
- 2001-01-29 US US09/772,123 patent/US6656685B2/en not_active Expired - Fee Related
-
2002
- 2002-01-29 JP JP2002561074A patent/JP2005503762A/ja active Pending
- 2002-01-29 WO PCT/US2002/002642 patent/WO2002061139A2/en not_active Ceased
- 2002-01-29 CA CA002434854A patent/CA2434854A1/en not_active Abandoned
- 2002-01-29 EP EP02706073A patent/EP1356116B1/en not_active Expired - Lifetime
- 2002-01-29 AU AU2002240180A patent/AU2002240180B2/en not_active Ceased
- 2002-01-29 AT AT02706073T patent/ATE361995T1/de not_active IP Right Cessation
- 2002-01-29 DE DE60220018T patent/DE60220018T2/de not_active Expired - Fee Related
-
2003
- 2003-08-28 US US10/652,676 patent/US20040253603A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002240180B2 (en) | 2006-02-09 |
| US20040253603A1 (en) | 2004-12-16 |
| CA2434854A1 (en) | 2002-08-08 |
| DE60220018D1 (de) | 2007-06-21 |
| EP1356116A2 (en) | 2003-10-29 |
| JP2005503762A (ja) | 2005-02-10 |
| US6656685B2 (en) | 2003-12-02 |
| WO2002061139A2 (en) | 2002-08-08 |
| US20020102554A1 (en) | 2002-08-01 |
| WO2002061139A3 (en) | 2003-04-03 |
| ATE361995T1 (de) | 2007-06-15 |
| EP1356116B1 (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60220018T2 (de) | Hybridisierungspuffer die niedermolekulares dextransulfat verwenden und methoden zu deren verwendung | |
| DE68928082T2 (de) | Manuelles in situ hybridisierungsverfahren | |
| DE69637065T2 (de) | Die bestimmung von nukleinsäuren und nukleinsäure-einheiten | |
| DE69635612T2 (de) | Detektion und amplifikation von nukleinsäuren durch chemische verbindung von oligonukleotiden | |
| DE68927059T3 (de) | In-situ-unterdrückungs-hybridisierung und verwendungen | |
| DE69232773T2 (de) | Vorrichtung zum Nachweis von Nukleinsäure-Amplifikations-Reaktionen | |
| DE69931497T2 (de) | Gel mikrotropfen für die genetische analyse | |
| DE69426807T2 (de) | Nukleinsäure-Amplifizierung bei SDA in Zellen | |
| DE69531133T2 (de) | Verfahren zur Dämpfung der Fluoreszene in Lösung von Fluoreszenzmarkierten Oligonucleotidsonden | |
| DE69421277T2 (de) | NUKLEINSäURE-SEQUENZANALYSE DURCH DIE METHODE DER PARALLELEN PRIMEREXTENSION | |
| DE69233458T2 (de) | Nukleinsäuretypisierung durch polymeraseverlängerung von oligonukleotiden unter verwendung von terminator-mischungen | |
| DE69506393T2 (de) | Hybridisation-ligitation-verfahren zum nachweis von spezifischen dns sequenzen | |
| DE69215533T2 (de) | In-situ-hybridisierungsmethode | |
| DE69029105T2 (de) | Schnellverfahren zum Nachweis und/oder zur Identifizierung einer Einzelbase in einer Nukleinsäuresequenz und seine Verwendungen | |
| AU2002240180A1 (en) | Hybridization buffers using low molecular weight dextran sulfate and methods for their use | |
| DE69829860T2 (de) | Spezies-übergreifendes anfärben von chromosomen | |
| DE69004632T2 (de) | Verfahren zum Nachweis von Nucleinsäuren. | |
| DE69900592T2 (de) | Verfahren zur unspezifischen amplifizierung einer nukleinsäure | |
| EP0745139A1 (de) | Verfahren zur präparierung und hybridisierung von spezifischen proben | |
| DE69917303T2 (de) | Genomische Multi-Loci Analyse durch ein Verfahren der verbesserten zyklischen Sequenzierung | |
| DE60113945T2 (de) | Verfahren zur Analyse von Wiederkehrenden PCR-Podukten, das auf der Analyse von DNS-Schmelzkurven basiert | |
| DE68928080T2 (de) | Einstufiges in situ-hybridierungstestverfahren | |
| DE10120798A1 (de) | Verfahren zur Bestimmung der Genexpression | |
| DE60119533T2 (de) | Verfahren zur erkennung des produkts einer nukleinsäuresynthetisierungsreaktion | |
| DE69933121T2 (de) | Methode, reagent und testsatz zur typisierung des genoms von papillomavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |